Left-sided portal hypertension from malignant islet cell tumour of the pancrease: review with a case report.

M Chellappa; C K Yee; D S Gill

Home/Archive/PubMed

PubMed · 3023606

Left-sided portal hypertension from malignant islet cell tumour of the pancrease: review with a case report.

M Chellappa·C K Yee·D S Gill

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Adenoma, Islet Cell Adult Female Humans Hypertension, Portal Pancreatic Neoplasms Splenic Vein Vascular Diseases Case Reports Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M Chellappa, C K Yee, D S Gill. 1986. Left-sided portal hypertension from malignant islet cell tumour of the pancrease: review with a case report.. https://pubmed.ncbi.nlm.nih.gov/3023606/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Cytotoxic action of 2-deoxy-D-glucose tetraacetate in tumoral pancreatic islet cells.

Tumoral insulin-producing cells of the RINm5F line were cultured for 8-96 h in the absence or presence of 2-deoxy-D-glucose (0.15-0.80 mM) or its tetraacetate ester (0.08-0.80 mM). Despite the fact that over a short incubation of 120 min the utilization of D-[5-3H]glucose and oxidation of D-[U-14C]glucose were not more markedly decreased by 2-deoxy-D-glucose tetraacetate than by the unesterified glucose analogue, the growth of the tumoral cells, as assessed by either the generation of formazan from 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide or direct cell counting, was more severely affected by the ester than by 2-deoxy-D-glucose. At a high concentration (0.80 mM), the ester even decreased the cell number below its initial value. No restoration of cell growth was observed when the cells were exposed for only 8 h to 2-deoxy-D-glucose tetraacetate (0.80 mM) and then further cultured for 64 h in the absence of the ester. These findings indicate that such an ester acts as a powerful cytostatic and cytotoxic agent in this tumoral cell line.

Adenoma, Islet Cell↗

PubMed1998

A causal role for E-cadherin in the transition from adenoma to carcinoma.

Development of malignant tumours is in part characterized by the ability of a tumour cell to overcome cell-cell adhesion and to invade surrounding tissue. E-cadherin is the main adhesion molecule of epithelia, and it has been implicated in carcinogenesis because it is frequently lost in human epithelial cancers. Re-establishing the functional cadherin complex in tumour cell lines results in a reversion from an invasive to a benign epithelial phenotype. However, it remained unresolved whether the loss of E-cadherin-mediated cell adhesion was a cause or a consequence of tumour progression in vivo. Here we report that the loss of E-cadherin expression coincides with the transition from well differentiated adenoma to invasive carcinoma in a transgenic mouse model of pancreatic beta-cell carcinogenesis (Rip1Tag2). Intercrossing Rip1Tag2 mice with transgenic mice that maintain E-cadherin expression in beta-tumour cells results in arrest of tumour development at the adenoma stage, whereas expression of a dominant-negative form of E-cadherin induces early invasion and metastasis. The results demonstrate that loss of E-cadherin-mediated cell adhesion is one rate-limiting step in the progression from adenoma to carcinoma.

Adenoma, Islet Cell↗

PubMed1998

Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia.

Non-islet cell tumour hypoglycaemia (NICTH) is characterised by severe and recurrent fasting hypoglycaemia, and is usually caused by secretion of insulin-like growth factor-II (IGF-II) by the tumour. This induces secondary changes in the circulating levels of insulin, growth hormone (GH), and the IGF-binding proteins (IGFBPs), resulting in an increased insulin-like hypoglycaemic activity of IGF-II. A participating role of IGF-I is not established. We measured serum levels of free IGF-I and free IGF-II, total IGF-I, total IGF-II, big IGF-II and IGFBP-1, IGFBP-2 and IGFBP-3 in patients with NICTH before (n=14) and after surgical removal of the tumour (n=3). A control group (n=20) was included for comparison. In NICTH patients, free IGF-II was 20-fold increased (26.8+/-8.1 [mean+/-SEM] vs. 1.3+/-0.1 microg/l), and free IGF-I was four fold increased (2.8+/-0.4 vs. 0.7+/-0.1 microg/l), as compared to control subjects (p < 0.0001). In accordance with earlier observations levels of total IGF-I, total IGF-II, and IGFBP-3 were decreased, whereas IGFBP-1 and IGFBP-2 were increased in NICTH (all p-values < 0.05). The highly elevated levels of free IGF-I and free IGF-II most likely imply a considerable hypoglycaemic insulin-like activity, and may, by negative feedback explain the marked suppression of the GH/IGF-I axis observed in NICTH. Finally, free IGF-II seems to be a powerful biochemical marker in the diagnosis of NICTH.

Adenoma, Islet Cell↗